Partnership to Create a Super Antiviral Drug
Because there are going to multiple strains of the influenza virus in circulation this fall, the Adamas Pharmaceuticals Inc. decided to sign a deal with the United States Navy so that they can begin working on a treatment for a variety of influenza virus strains.
The United States Naval Research Center agreed that it will conduct preclinical trails on the Adamas' triple combination antiviral drug. The optimal case would be to have one antiviral drug that would be able to treat several strains of the flu.
After the experiments are conducted, the information will be used to advance the broad-spectrum antiviral therapy of serious infections caused by all type A influenza viruses.
